First human trial of AstraZeneca coronavirus vaccine shows promise
Pfizer, BioNTech coronavirus vaccine response ‘extremely important’: Dr. Marc Siegel
Fox News medical contributor on Pfizer and BioNTech’s promising coronavirus vaccine results, potential news on AstraZeneca’s vaccine and the importance of wearing a face mask to help stop the spread.
LONDON (Reuters) – AstraZeneca's experimental COVID-19 vaccine was safe and produced an immune response in early-stage clinical trials in healthy volunteers, data showed on Monday.
Continue Reading Below
The vaccine, called AZD1222 and being developed by AstraZeneca and scientists at Britain's University of Oxford, did not prompt any serious side effects and elicited antibody and T-cell immune responses, according to trial results published in The Lancet medical journal.
PFIZER-BIONTECH POTENTIAL CORONAVIRUS VACCINE SHOWS PROMISE IN ADDITIONAL DATA
"We hope this means the immune system will remember the virus, so that our vaccine will protect people for an extended period," study lead author Andrew Pollard of the University of Oxford said.
Ticker | Security | Last | Change | Change % |
---|---|---|---|---|
AZN | ASTRAZENECA PLC | 59.50 | -1.60 | -2.62% |
"However, we need more research before we can confirm the vaccine effectively protects against SARS-CoV-2 (COVID-19) infection, and for how long any protection lasts," he said.
POPULAR VACATION DESTINATION BANS US TOURIST TRAVEL AS CORONAVIRUS CASES SPIKE
AstraZeneca's is among the leading vaccine candidates against a pandemic that has claimed more than 600,000 lives, alongside others in mid and late-stage trials.